Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Z. Chen, W. Wang, J. E. Cortes, E. Liu, R. N. Miranda, C. Zhao, J. Yuan, X. Lu, W. Yang, M. D. Ameri, H. M. Kantarjian, L. J. Medeiros, S. Hu

Research output: Contribution to journalLetter

3 Scopus citations
Original languageEnglish (US)
Article numbere418
JournalBlood Cancer Journal
Volume6
DOIs
StatePublished - May 6 2016
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Chen, Z., Wang, W., Cortes, J. E., Liu, E., Miranda, R. N., Zhao, C., Yuan, J., Lu, X., Yang, W., Ameri, M. D., Kantarjian, H. M., Medeiros, L. J., & Hu, S. (2016). Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer Journal, 6, [e418]. https://doi.org/10.1038/bcj.2016.27